Product NDC: | 61703-303 |
Proprietary Name: | CYTARABINE |
Non Proprietary Name: | CYTARABINE |
Active Ingredient(s): | 20 mg/mL & nbsp; CYTARABINE |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 61703-303 |
Labeler Name: | Hospira Worldwide, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA072168 |
Marketing Category: | ANDA |
Start Marketing Date: | 19900831 |
Package NDC: | 61703-303-46 |
Package Description: | 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (61703-303-46) > 50 mL in 1 VIAL, PHARMACY BULK PACKAGE |
NDC Code | 61703-303-46 |
Proprietary Name | CYTARABINE |
Package Description | 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (61703-303-46) > 50 mL in 1 VIAL, PHARMACY BULK PACKAGE |
Product NDC | 61703-303 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | CYTARABINE |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 19900831 |
Marketing Category Name | ANDA |
Labeler Name | Hospira Worldwide, Inc. |
Substance Name | CYTARABINE |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |